---
document_datetime: 2025-11-18 16:26:12
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/oslif-breezhaler-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: oslif-breezhaler-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.694561
conversion_datetime: 2025-12-26 12:00:43.274319
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Oslif Breezhaler

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | This was an application for a group of | 18/11/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308592   | variations.   | PL   |
|---------------------|---------------|------|

<div style=\"page-break-after: always\"></div>

|                                     | intermediate/orexcipientfromanewor an already approved manufacturer- Accepted B.IIl.1.bEuropeanPharmacopoeial TSE Certificateofsuitabilityforanactive substance/startingmaterial/reagent/ intermediate/or excipient-B.1II1.1.b.2 New certificate for a starting material/reagent/ intermediate/orexcipientfrom anewor an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                               |            |                        |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation typeIB/ EMA/VR/0000280314 | This was an applicationfor avariation following a worksharing procedure according toArticle20of CommissionRegulation(EC) No 1234/2008. C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.z Implementation of QRD template-Accepted C.I.z-toaddinsection6.1oftheSmPC andsection6of thePackageLeafletthelist ofexcipientstoincludethecomplete componentsofcapsuleshell andprintingink under a separate heading \"Capsule Shell\". TheMAHalso tookthisopportunity to removefrom theexcipientslistthe components of the printing inks that are eliminated during processing. Additionally, the MAH is proposing editorial changes in the Product Information as follows:- | 04/09/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | twocapsule strengths(150and300 microgram capsules)intoa singleSmPC coveringboth strengths.-SmPC-Section 1,2,3,4.2,4.8,6.1 and 8;-Package Leaflet - Section 6;- Update to latest QRD template (10.4). Finally, the MAH took the opportunity to edit/format/amend/correct minor typos in following sections: - SmPC - Section 4.4, 4.8, 5.1, 5.2 and 10 ; - Labelling - Section 3 and 14; - Package Leaflet-Section2,3,4 and toupdate the Icelandic contactdetailsinthelistof Local representative of the Marketing AuthorisationHolderinsection6ofthe Package Leaflet.                                                       |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000244589 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product -B.Il.b.5.aTightening of in- process limits - Accepted B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused inthemanufacturingprocessoftheactive substanceorchangeinthemanufacturer (includingwhererelevantquality control testingsites)oftheactivesubstance,where noPh.Eur.Certificate ofSuitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of asitewherebatchcontrol/testingtakes | 13/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

## place -Accepted

B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substanceorchangeinthemanufacturer (including where relevant quality control testing sites) of the active substance, where noPh.Eur.Certificate of Suitability is part of the approved dossier-B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of asitewherebatchcontrol/testingtakes place - Accepted

A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesfor an active substance, intermediate or finished product, packaging site, manufacturer responsible for batchrelease,sitewherebatchcontroltakes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)*- Accepted